{
  "id": 3253572,
  "title": "Why is Immatics stock climbing today?",
  "url": "https://urgent.news/2026/08/25/why-is-immatics-stock-climbing-today",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-25T11:50:32.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/why-is-immatics-stock-climbing-today-93CH-4875182"
  },
  "original_language": "en",
  "account": "Imatics stock experienced a significant increase of nearly 4.7% in pre-market trading, reaching a price of $9.10. The company disclosed plans to sell 12,945,916 shares and 4,315,304 pre-funded warrants at $8.69 per share each, totaling a $150 million underwritten public offering. This announcement was bolstered by a reaffirmation of its Buy rating from Goldman Sachs, an investment bank. The endorsement came in the early pre-market hours, shortly after Immatics released its second-quarter 2026 interim financial results, providing investors with positive signals ahead of the opening bell. The company's strong performance and recent achievements have contributed to a strong consensus among analysts, with a majority rating it as a Strong Buy and assigning average price targets ranging from $17 to $19, more than double the current pre-market price. Additionally, the broader NASDAQ Composite is also on the rise, providing a supportive macro tailwind for growth-oriented biotech stocks. Together, these factors – the share offering, recent earnings beat, clinical milestones, and Goldman Sachs' Buy reaffirmation – have created an attractive pre-market setup for Immatics, despite the stock trading below its 52-week high of $12.41. Analysts broadly expect significant upside for the company as it progresses toward its first potential commercial product.",
  "summary": null,
  "key_points": [
    "Immatics shares rose 4.7% in pre-market trading to $9.10.",
    "Company announced $150 million underwritten public offering.",
    "Goldman Sachs reaffirmed Buy rating, analysts expect strong upside."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}